Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Hold” by Analysts

Hologic, Inc. (NASDAQ:HOLX) has earned a consensus recommendation of “Hold” from the nineteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Twelve research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $79.00.

Several brokerages have recently weighed in on HOLX. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Stephens restated an “equal weight” rating and issued a $76.00 target price (down from $78.00) on shares of Hologic in a research report on Wednesday. Finally, Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st.

Hologic Stock Performance

Hologic stock opened at $73.93 on Friday. The company has a market capitalization of $16.44 billion, a price-to-earnings ratio of 30.68, a PEG ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The stock has a fifty day moving average of $67.41 and a two-hundred day moving average of $63.76.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the business earned $1.06 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

Several hedge funds and other institutional investors have recently modified their holdings of HOLX. Chung Wu Investment Group LLC acquired a new stake in Hologic during the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. SJS Investment Consulting Inc. boosted its position in Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in Hologic during the second quarter valued at $33,000. Finally, Zions Bancorporation National Association UT acquired a new stake in Hologic during the first quarter valued at $34,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.